Related Experiment Videos
PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells
1Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, California 94305-5236, USA.
Abstract:
Progress in the treatment of solid tumors has been slow and sporadic. The efficacy of conventional chemotherapy in solid tumors is limited because tumors frequently have mutations in the p53 gene. Also, chemotherapy only kills rapidly dividing cells. Members of the tumor necrosis factor (TNF) family, however, induce apoptosis regardless of the p53 phenotype. Unfortunately, the cytotoxicity of TNF-alpha is limited by its activation of NF-kappaB and activation of NF-kappaB is proinflammatory. We have identified a compound called PG490, that is composed of purified triptolide, which induces apoptosis in tumor cells and sensitizes tumor cells to TNF-alpha-induced apoptosis. PG490 potently inhibited TNF-alpha-induced activation of NF-kappaB. PG490 also blocked TNF-alpha-mediated induction of c-IAP2 (hiap-1) and c-IAP1 (hiap-2), members of the inhibitor of apoptosis (IAP) family. Interestingly, PG490 did not block DNA binding of NF-kappaB, but it blocked transactivation of NF-kappaB. Our identification of a compound that blocks TNF-alpha-induced activation of NF-kappaB may enhance the cytotoxicity of TNF-alpha on tumors in vivo and limit its proinflammatory effects.
Insights
A novel compound, PG490 (triptolide), enhances tumor necrosis factor-alpha (TNF-alpha) cancer therapy by inducing apoptosis and blocking NF-kappaB activation. This approach may improve solid tumor treatment efficacy and reduce inflammation.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Conventional chemotherapy efficacy for solid tumors is limited by p53 gene mutations and inability to target non-dividing cells.
- Tumor necrosis factor-alpha (TNF-alpha) induces apoptosis irrespective of p53 status but its antitumor effects are hindered by NF-kappaB activation, which causes inflammation.
Purpose of the Study:
- To identify compounds that can enhance TNF-alpha's efficacy against solid tumors while mitigating its inflammatory side effects.
- To investigate the mechanism by which PG490 interacts with TNF-alpha signaling pathways.
Main Methods:
- Treatment of tumor cells with PG490 and TNF-alpha.
- Analysis of NF-kappaB activation, DNA binding, and transactivation.
- Assessment of inhibitor of apoptosis (IAP) protein induction.
Main Results:
- PG490, derived from triptolide, induces apoptosis in tumor cells and sensitizes them to TNF-alpha.
- PG490 potently inhibits TNF-alpha-induced NF-kappaB activation by blocking transactivation, not DNA binding.
- PG490 blocks TNF-alpha-mediated induction of c-IAP2 and c-IAP1, key regulators of apoptosis.
Conclusions:
- PG490 represents a promising therapeutic agent for solid tumors by enhancing TNF-alpha cytotoxicity.
- Blocking TNF-alpha-induced NF-kappaB activation with PG490 may improve in vivo tumor treatment and reduce associated inflammation.